Encompass Health (EHC) Q3 2026 Earnings Call Transcript

Encompass Health reported Q3 2026 revenue of $1,609.5 million, up 8.9%; adjusted EBITDA rose 15.5% to $346.6 million and adjusted EPS increased 23.6% to $1.52. The company raised full-year guidance to $6.45–$6.50 billion in revenue, $1.395–$1.415 billion in adjusted EBITDA and $6.23–$6.37 in adjusted EPS. Discharge growth, higher patient acuity and capacity expansion supported results, while a billing-system conversion temporarily lifted bad debt expense to 2.7%; management expects it to normalize to 2%–2.5% in Q4. Risks include CMS approval uncertainty for Florida supplemental payments and Palmetto’s capacity to handle a 10-fold increase in claims volume as review requirements expand to 75 additional hospitals in January 2027.

Analysis

EHC’s key earnings-quality question is whether growth can remain volume-led as capacity, rather than demand, constrains throughput. The upside is operational leverage from filling beds and improving acuity mix; the offset is that new hospitals carry ramp costs before reaching mature occupancy, while bed additions and North Carolina expansion compete for management and construction capacity. The small-format model could improve returns, but its 2028–29 scaling case remains conditional on licensing templates and the first sites proving out.

The near-term risk is less clinical eligibility than claims administration. The 75-hospital RCD rollout puts Palmetto’s processing capacity under stress: even with strong affirmation rates, payment delays could raise reserves and working-capital needs in 1H27. The billing-system backlog is described as temporary, but verify managed-care/MA claims aging and bad debt normalize before underwriting that as resolved. Separately, Florida supplemental-payment approval is an upside contingency, not a base-case earnings driver.

Acuity and pricing are supportive but not an unqualified structural tailwind. MA authorization pressure can displace lower-acuity admissions, and successful appeals may recover volume; however, the pilot’s claim count is small and added appeal staffing may absorb some benefit. Pricing comparisons also become tougher after the recent acuity lift laps. The market may over-focus on raised 2026 guidance and underweight execution/cash-conversion risk in 2027; conversely, the operating platform and low leverage provide room to invest without forcing balance-sheet risk.

Key Decisions for Investors

• Do not chase an opening gap on the guidance raise. Consider initiating or adding to EHC on post-earnings weakness, contingent on Q4 bad debt returning toward management’s stated 2%–2.5% range and evidence that managed-care/MA claims queues are clearing.
• Treat the 2027 RCD launch as the main 1–3 month watch item: track CMS/Palmetto implementation details, affirmation rates, denial-to-appeal outcomes, and receivables aging. A material rise in bad debt or persistent collection delays would falsify the normalization thesis and warrant reducing exposure.
• Underwrite capacity returns selectively: favor existing-hospital bed additions over headline pipeline counts until the first small-format sites demonstrate occupancy ramp and targeted returns. Monitor 2027 startup costs, opening schedules, and whether high-occupancy hospitals actually receive planned beds.
• Keep Florida Medicaid approval out of base estimates; treat any CMS approval as event-driven upside. Reassess if guidance or cash flow begins to rely on uncertain supplemental payments rather than core discharge growth and operating efficiency.